Comparative Pharmacology
Head-to-head clinical analysis: ANECTINE versus METOCURINE IODIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANECTINE versus METOCURINE IODIDE.
ANECTINE vs METOCURINE IODIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depolarizing neuromuscular blocker; mimics acetylcholine at nicotinic receptors at the neuromuscular junction, causing sustained depolarization and receptor desensitization.
Competitive nicotinic acetylcholine receptor antagonist at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
1-1.5 mg/kg IV bolus for intubation; maintenance infusion: 2.5-4.3 mg/min IV; alternatively, 3-4 mg/kg IM for intubation.
Initial dose 0.2 mg/kg IV; maintenance doses of 0.1-0.15 mg/kg IV as needed for neuromuscular blockade.
None Documented
None Documented
2-5 minutes (pseudocholinesterase hydrolysis); terminal half-life of succinylmonocholine ~30-60 minutes; clinical duration of apnea determined by rapid initial hydrolysis
Terminal elimination half-life: 3-5 hours in patients with normal renal function. Prolonged in renal impairment.
Renal: 10-15% unchanged; hepatic: rapid hydrolysis by plasma pseudocholinesterase (butyrylcholinesterase) to succinylmonocholine and succinic acid; <2% biliary; <2% fecal
Renal: 85-90% unchanged; biliary/fecal: <5%.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker